-
J&J’s $10 Billion Chapter 11 Asbestos Settlement Trial Begins in Texas
Over the last several years, Johnson & Johnson has been fending off personal injury lawsuits filed by mesothelioma and ovarian cancer victims who blame the company’s talc-based products for their illnesses. The company has attempted several controversial bankruptcy filings with increasing settlement offers for talc claimants, but each has been denied by courts and rejected
-
Washington State Woman’s Mesothelioma Blamed on Asbestos in Talc Products
A Washington state woman and her husband have filed suit against multiple defendants, including Colgate-Palmolive, accusing them of being responsible for her malignant mesothelioma diagnosis. Linda A. Stange and her husband, Arlen, blame asbestos in talc that she used personally, as well as asbestos in talc products that her husband used personally and was exposed
-
UK Scientists to Explore Mesothelioma Latency
Researchers across the United Kingdom are recruiting participants for a mesothelioma study being funded by Cancer Research UK. The project, called Meso-ORIGINS, hopes to discover why mesothelioma’s tumors take decades to develop in people who have been exposed to asbestos.
-
UK Researchers Report Progress in Developing Mesothelioma Breath Test
Early diagnosis makes a significant difference in malignant mesothelioma’s outcome and options, but it rarely happens because the cancer’s symptoms don’t appear until its fatal tumors are large and advanced. This week, researchers at a public research university in Sheffield, England, in the United Kingdom, reported developing a breath “fingerprint” that could make a real
-
Wisconsin Cancer Center Reports Success in Mesothelioma Treatment
Malignant pleural mesothelioma is a notoriously difficult form of cancer to treat. The aggressive, asbestos-related disease is always considered fatal, with most patients succumbing to their illness within a year of diagnosis. However, the Froedtert & the Medical College of Wisconsin health network recently reported good results after treating a patient with immunotherapy drugs.
-
Mesothelioma Advocates Watch as EPA Takes Asbestos Ban Argument to 5th Circuit
For Americans whose lives have been touched by malignant mesothelioma, a U.S. ban on asbestos is a long-held goal, so the EPA’s presentation this week to the 5th Circuit Court of Appeals is garnering significant attention. While the agency is defending its recent rule prohibiting the ongoing use of chrysotile asbestos, industry groups and a noted
-
Will Federal Funding Freeze Impact Mesothelioma Research?
Mesothelioma researchers, physicians, and patients are concerned that recent funding cuts may stall groundbreaking innovations in treating the rare and deadly disease. Though the freeze on funding does not affect patient care, it will impact the ability to operate and maintain the facilities and laboratories in which critical tests and clinical trials are performed. Academic
-
Mesothelioma and Ovarian Cancer Victims in UK Prepare to Sue Johnson & Johnson
Following the filing of over 40,000 ovarian cancer and mesothelioma claims against Johnson & Johnson in the United States, thousands of people in the United Kingdom are preparing to file similar lawsuits. All of the victims accuse the pharmaceutical firm of exposing them to the risk of cancer through asbestos contamination of their popular talcum
-
PA Supreme Court Allows Engineer’s Mesothelioma Claim Against University Employer
The Pennsylvania Supreme Court handed down a groundbreaking 52-page opinion in a mesothelioma lawsuit filed by the family of a stationary engineer against the University of Pittsburgh. The court upheld lower courts’ decisions that employees whose occupational diseases develop beyond the limits of the workers’ compensation and Occupational Disease Act have the right to file
-
Automotive Consultant’s Mesothelioma Death Blamed on Asbestos-Containing Auto Parts
After John Beagan died of mesothelioma in 2019, his family filed a personal injury lawsuit in the New York state courts against multiple defendants. Two defendants argued that the New York claim should be dismissed for jurisdictional reasons, but the lower and appellate courts denied their arguments.
-
Research is Driving a Shift in Focus for Mesothelioma Treatment
A report generated by leading market research firm IMARC Group concludes that there has been a significant transformation in the treatment landscape for malignant mesothelioma. The group anticipates that investment in mesothelioma treatments will more than double over the next ten years from $464.2 million in 2024 to $972 million by 2035. They say that the
-
Mesothelioma Widow Succeeds in Barring Testimony from Memory Expert
A mesothelioma widow seeking justice on behalf of her late husband saw a victory in court when the Superior Court of Delaware granted her request to exclude testimony from a noted memory retention expert hired by the single defendant, asbestos company J-M Manufacturing Company. Ladonna Sue Braxton successfully argued that his testimony would invade the
-
Minnesota Couple Impacted by Mesothelioma Prevails Against Former Employer
A mesothelioma lawsuit filed in the state of Minnesota has seen a man include his former employer among the named defendants in his personal injury claim. When the company asked to be dismissed from the case based on the state’s Workers’ Compensation Act, the couple successfully argued that his occupational exposure to the company’s asbestos
-
Study Reveals Potential Treatment for Mesothelioma and Other Cancers
Mesothelioma is one of the most challenging forms of cancer to treat. The aggressive disease has proven resistant to traditional protocols and is always considered fatal. This week a study reveals a new way to combat therapy-resistant cancers, and mesothelioma researchers are hoping that it can be applied to the rare and deadly asbestos-related malignancy.
-
Woman’s Mesothelioma Case Delayed by Bankruptcy Filing
Irma Lee Lagrange was diagnosed with malignant mesothelioma after years of having laundered her husband Allen’s work clothes. Before her death, she filed suit against multiple companies seeking compensation for the harm she suffered, but her case was temporarily stopped in light of one of the defendants’ bankruptcy filing.
-
Mesothelioma Concerns Drive Cambodia to Consider Banning Asbestos
Facing increasing concerns about malignant mesothelioma and other health impacts of asbestos, the government of Cambodia has announced that it is considering a total ban on its use in the country.
-
Talc Victims and U.S. Trustee’s Office Object to J&J’s $9 Billion Bankruptcy Proposal
For the last several years, Johnson & Johnson has been ordered to pay millions of dollars in compensation to victims of mesothelioma and ovarian cancer. With tens of thousands of such claims pending, the company has made multiple attempts to convince bankruptcy judges to allow them to assign all of their asbestos liabilities to newly
-
Illinois Supreme Court Allows Workers’ Comp Claims for Mesothelioma
Mesothelioma victims whose occupational exposure to asbestos have numerous options for seeking compensation, including filing claims for workers’ compensation benefits, but some state’s rules have blocked these claims. When an Illinois widow argued that her claim against her late husband’s employer should be allowed, the state’s Supreme Court justices agreed, ruling that diseases that appear
-
Court Hears Arguments About $30M Mesothelioma Punitive Damages Award
Johnson & Johnson has responded to a Connecticut mesothelioma victim requesting a $30 million punitive damages award, arguing that the victim’s request to the jury intentionally meets the state-law-mandated maximum, and is unwarranted by the facts of the case.
-
AI-driven Biotech Company Begins Phase I Trial of Mesothelioma Drug
Biotechnology company Insilico Medicine has announced the dosing of the first patient in a global Phase I trial of its newest mesothelioma drug innovation. The company’s chief medical officer, Sujata Rao, MD, says that ISM6331 was developed to prevent the proliferation and survival of tumor cells, doing so by blocking the transcription of multiple genes
